Regulated information

2009 annual earnings

March 31, 2010 – (Lure, France) – Vétoquinol’s Board of Directors, meeting on March 11, 2010, reviewed the Group’s business and approved its 2009 financial statements.

BOREVE-D: Vétoquinol is participating in a project to raise awareness of the need to treat pain in cattle

June 30, 2010 (Lure, France) – Vétoquinol, in collaboration with two other veterinary laboratories, is participating in a project organised by the Syndicat de l’Industrie du Médicament Vétérinaire (SIMV) to raise awareness of the need to treat pain in cattle.

Continued sales growth driven by sustained organic growth

April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition.

Continued Sales Growth in the second Quarter of 2010

Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth.

Departure of Pierre Konareff

April 14, 2010 (Lure, France) – The Vétoquinol Group today announces the departure of Pierre
Konareff, Group Director of Finance and Legal Affairs, because of differences concerning his
position in the Group. Pierre Konareff joined Vétoquinol in July 2008.

Mise à disposition ou de consultation du rapport financier semestriel 2010 (french)

Le Rapport financier semestriel 2010 de Vétoquinol peut être consulté ou téléchargé sur
le site Internet de la société : www.vetoquinol.com, rubrique « Investisseurs & Journalistes ».

Redemption of tranche A bonds

February 26, 2010 (Lure, France) - Following the decision of Soparfin (family holding Etienne Frechin) not to convert the tranche A convertible bonds when they reach maturity on February 27, 2010, Vétoquinol has redeemed the bonds.

Strong growth in 2009 Revenues: +7.6%

January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions.

Strong Results in the first half of 2010

The Board of Directors of Vétoquinol, meeting on August 30, reviewed the group’s business and approved its interim 2010 financial statements.

Strong Sales in the 3rd Quarter of 2010

Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments.